HK Stock Market Move | ALPHAMAB-B(09966) rose over 3% recently. JSKN003 will release its latest research results at the 2024 ESMO conference.

ALPHAMAB-B (09966) rose more than 3%. As of the time of writing, it rose by 3.16% to 2.61 Hong Kong dollars, with a turnover of 8.2645 million Hong Kong dollars. On the news front, recently, ALPHAMAB-B announced that the latest results of the Phase I clinical trial of JSKN003 for the treatment of late-stage/metastatic solid tumor patients in Australia, and the Phase I/II clinical trial for the treatment of late-stage solid tumor patients in mainland China, were presented during the 2024 ESMO conference. The conclusion was that JSKN003 showed good tolerability and safety, with a low incidence of gastrointestinal and hematologic toxicity, and showed encouraging efficacy in PROC patients who had received multiple lines of treatment. It is reported that JSKN003-101 is a first-in-human, open-label, multicenter Phase I clinical trial conducted in late-stage/metastatic solid tumor patients in Australia, consisting of dose escalation and dose expansion stages. JSKN003-102 is a Phase I (dose escalation and dose expansion) and Phase II (cohort expansion) clinical trial conducted in late-stage solid tumor patients in China.